Last reviewed · How we verify
NCT05527457
BAY2586116 Nasal Spray and OSA Severity
Phase 1 trial testing BAY2586116 in Sleep Apnea, Obstructive in 10 participants. Completed in 20 December 2022.
20 December 2022
Quick facts
| Lead sponsor | Flinders University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 31 August 2022 |
| Primary completion | 20 December 2022 |
| Estimated completion | 20 December 2022 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- BAY2586116 — full drug profile →
- Placebo
Conditions studied
- Sleep Apnea, Obstructive — all drugs for Sleep Apnea, Obstructive →
Sponsor
Flinders University
Who can join
18 and older, any sex, with Sleep Apnea, Obstructive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This investigator-initiated study aims to determine the effects of BAY2586116 (a novel TASK channel blocker nasal spray) on sleep apnoea severity and the potential influence of route of breathing.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05527457
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BAY2586116
Trials testing the same drug.
- NCT04872387 — A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the B · Phase 1 · completed
- NCT04713826 — A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstruc · Phase 2 · completed
Other recruiting trials for Sleep Apnea, Obstructive
Currently open trials in the same condition.
- NCT06828835 — The REPOSE (Reach for Equity in Pediatric Sleep Evaluation) Navigation Intervention · NA · recruiting
- NCT06915831 — Type 1 Diabetes and Obstructive Sleep Apnea · NA · recruiting
- NCT07176767 — The IPAD Cohort Study: Insomnia and Positive Airway Pressure Adherence in Children and Adolescents · recruiting
- NCT06573372 — Evaluating the Diagnostic Efficacy of Smartwatch and Smartphone for Sleep Apnea · recruiting
- NCT06848647 — Treatment of Sleep Apnea to Improve Metabolic Health · recruiting
Other Flinders University trials
Trials by the same sponsor.
- NCT06928766 — Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping · Phase 2 · not yet recruiting
- NCT05303935 — Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea · Phase 2 · completed
- NCT05349058 — Assessment of Myocardial Injury in Patients Treated With Immune Checkpoint Inhibitors · unknown
- NCT04426578 — Role of Perhexiline in Hypertrophic Cardiomyopathy · Phase 2 · unknown
- NCT04128891 — Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction · Phase 3 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05527457 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Flinders University
- Last refreshed: 15 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05527457.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing